Zogenix Inc - ESG Rating & Company Profile powered by AI
This analysis of Zogenix Inc employs intelligence from across the web as well as from public disclosures by Zogenix Inc. Alternative corporations in the rating industry group for Zogenix Inc are displayed below. Detailed Sustainability analysis of Zogenix Inc can be accessed by registering for free.
Zogenix Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.7; made up of an environmental score of 6.0, social score of 6.4 and governance score of 1.6.
4.7
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 816 | Pliant Therapeutics Inc | 4.8 | High |
| 816 | Voyager Therapeutics Inc | 4.8 | High |
| 837 | Zogenix Inc | 4.7 | High |
| 837 | Bio Rad Laboratories Inc | 4.7 | High |
| 837 | Katakura Industries Co Ltd | 4.7 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Zogenix Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Zogenix Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Zogenix Inc report the average age of the workforce?
Sign up for free to unlockDoes Zogenix Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Zogenix Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Zogenix Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Zogenix Inc offer flexible work?
Sign up for free to unlockDoes Zogenix Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Zogenix Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Zogenix Inc conduct supply chain audits?
Sign up for free to unlockDoes Zogenix Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Zogenix Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Zogenix Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Zogenix Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Zogenix Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Zogenix Inc disclose water use targets?
Sign up for free to unlockDoes Zogenix Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Zogenix Inc have a product recall in the last two years?
Sign up for free to unlockDoes Zogenix Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Zogenix Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Zogenix Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Zogenix Inc disclose parental leave metrics?
Sign up for free to unlockDoes Zogenix Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Zogenix Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Zogenix Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Zogenix Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Zogenix Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Zogenix Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Zogenix Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Zogenix Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Zogenix Inc disclose its waste policy?
Sign up for free to unlockDoes Zogenix Inc report according to TCFD requirements?
Sign up for free to unlockDoes Zogenix Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Zogenix Inc disclose energy use targets?
Sign up for free to unlockDoes Zogenix Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Zogenix Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Zogenix Inc
These potential risks are based on the size, segment and geographies of the company.
Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also developing MT1621, an investigational therapy for the treatment of a rare genetic disorder called thymidine kinase 2 deficiency. Zogenix, Inc. has a collaboration with Tevard Biosciences for the research, development and commercialization of novel gene therapies for Dravet Syndrome and other genetic epilepsies. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was incorporated in 2006 and is headquartered in Emeryville, California.